Skip to main content

Table 1 Characteristics of included RCTs

From: Potential effectiveness of Chinese herbal medicine Yu ping feng san for adult allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials

First author, publication year, country Treatment duration, follow-up duration Duration of AR (mean (SD)) Number of participants of randomized/ assessed Age (mean (SD) or range in years), gender (M/F) Intervention (route of administration) Control (route of administration, dosage) Adverse events (number of events)
1 YPFS vs placebo
 Chan 2014 [14], Hong Kong China 4 weeks, 3 months I: >1 year;
C: >1 year
I: 83/80;
C:83/79
I: 18–25, 32/48;
C: 18–25, 35/44
Modified YPFS (oral) Placebo (oral, 70 ml each time, once per day) Increased acne and abdominal distension (4)
 Feng 2004 [15], China 8 weeks, NS I:10.57 (7.31) years
C:11.31 (8.17) years
I: 43/43;
C: 43/43
I: 37.74 (14.57), 22/21;
C: 38.17 (14.21), 22/21
Allergic Rhinitis oral liquid (oral) Saline (oral, 20 ml each time, three times a day) NS
2 YPFS vs pharmacotherapy
 Fang 2014 [16], China 1 month, NS I: 3.26 (1.27) years;
C: 3.17 (1.12) years
I: 118/118;
C: 102/102
I: 35.18 (13.72), 53/65;
C: 36.03(12.85), 43/59
Yu ping feng capsule
(oral)
Cetirizine Hydrochlorde (oral, 10 mg once per day), Budesonide aerosol (nasal spray, twice per day) No AE
 Wang 2014 [17], China 14 days, NS I: NS;
C: NS
I: 30/30;
C: 30/30
I: 33 (10.78), 14/16;
C:35 (11.94), 15/15
Modified YPFS
(oral)
Cetirizine Hydrochloride (oral, 10 mg once per day) NS
 Luo 2012 [18], China 28 days, 1 year I: 4.34 (4.29) years
C: 4.52 (4.45) years
I: 60/60;
C: 60/60
I: 34.64 (11.35), 38/22;
C: 35.20 (10.43), 34/26
Modified YPFS (oral) Cetirizine Hydrochloride
(oral, 10 mg once per day)
NS
 Wu 2013 [19], China 14 days, 1 year I: 5 (1–11) years;
C: 6 (1–8) years
I: 50/50;
C: 50/50
I: 36, 22/28;
C: 39, 27/23
Yu ping zhi ti granule (oral) Loratadine (oral, 10 mg before bedtime) NS
 Wang 2009 [20], China 14 days, 1 month I: 4.34 (4.29) years;
C: 4.52 (4.45) years
I: 30/30;
C: 30/30
I: 34.64 (11.35), 19/11;
C: 35.2 (10.43), 17/13
Modified YPFS (oral) Cetirizine Hydrochloride (oral, 10 mg once per day) NS
 Guo 2015 [21], China 15 days, NS I: NS;
C:NS
I: 35/35;
C: 35/35
I: 26.5 (6.3), 20/15;
C: 32 (4.3), 16 /19
Yu ping feng granule
(oral)
Cetirizine Hydrochloride (oral, 10 mg once per day) NS
 Yao 2015 [22], China 4 weeks, NS I: 8. 8(3.5) years;
C: 8.6 (3.1) years
I: 43/43;
C: 40/40
I: 41.8 (5.5), 18/25;
C: 40.3 (4.9), 17 /23
Modified YPFS (oral) Cetirizine Hydrochlorde (oral, 10 mg before bedtime) No AE
3 YPFS + pharmacotherapy vs pharmacotherapy
 Shi 2014 [24], China 28 days, No follow up I: 4.18 (2.82) years;
C: 4.67 (2.33) years
I: 44/44;
C: 32/32
I: 36.5 (17.5), 23/21
C: 37.5 (16.5), 17/15
Yu ping feng drop pill and Cetirizine (oral) Cetirizine (oral, 10 mg once per day) No AE
 Lu 2014 [25], China 2 weeks, 8 weeks I: (1 month-3 years);
C: (1 month-2.5 years)
I: 40/40
C: 40/40
I: 40.3 (10.5), 28/12;
C: 38.0 (11.2), 27/13
Yu ping feng granule (oral) + Ebastine (oral), Fluticasone propionate (nasal spray) Ebastine (oral, 10 mg once per day), Fluticasone propionate (nasal spray, two sprays each nostril, once per day) No AE
 Zhou 2010 [26], China 1 month; NS I: NS;
C:NS
I: 36/36;
C: 36/36
I: 45.5, 15/21;
C: 43.6, 15/21
Yu ping feng granule (oral)
+ Budesonide aerosol (nasal spray)
Budesonide aerosol (nasal spray, two sprays each nostril, twice per day) No AE
 Huang 2014 [27], China 4 weeks; 3 months I: 12.7 (3.1) months;
C:11.2 (2.5) months
I: 74/74;
C: 71/71
I: 30.3 (3.4), 40/34;
C: 31.2 (2.7), 38/33
Modified YPFS (oral)
+ Cetirizine Hydrochloride (oral); Budesonide aerosol (nasal spray)
Cetirizine Hydrochloride (oral, one spray each nostril, twice per day), Budesonide aerosol (nasal spray, 10 mg once per day) NS
 Liu 2012 [28], China 30 days; NS I: 4 years;
C: 4 years
I: 30/28;
C: 30/29
I: 39.25 (5.58), 13/15;
C: 39.97 (4.15), 15/14
Modified YPFS
+ Loratadine (oral)
Loratadine (oral, 10 mg once per day) No AE
 Chen 2014 [29], China 28 days; 6 months I: NS;
C: NS
I: 60/60;
C: 60/60
I: NS, NS;
C: NS, NS
Modified YPFS + Cetirizine (oral) Cetirizine (oral, 10 mg once per day) I: skin rash (2), vomit (1), nausea (2); C:skin rash (5), vomit (4), nausea (3)
 Lin 2014 [30], China 30 days; NS I: 4.25 (1) years;
C:4.28 (1.05) years
I: 30/28;
C: 30/29
I:33.18 (11.42), 16/12;
C:33.89 (9.35), 16/13
Modified YPFS + Cetirizine (oral) Cetirizine (oral, 10 mg once per day) No AE
 Guan 2013 [31], China 14 days; NS I: NS;
C: NS
I: 27/27;
C: 26/26
I: NS, NS;
C: NS, NS
YPFS (oral) + Budesonide aerosol (nasal spray) Budesonide aerosol (nasal spray, 64μg each nostril, twice per day) I: sedation (1), local mucosa irritation (2); C: local mucosa irritation (2), skin rash (2)
 Chen 2015 [32],China 21 days; NS I: 5.92(4.07) years;
C: 6.16(4.39) years
I: 63/63;
C: 63/63
I:35.36 (7.19), 35/28;
C:34.18 (6.82), 33/30
Modified YPFS (oral)
+ Azelastine (nasal spray);
Azelastine (nasal spray, one spray each nostril, twice per day) NS
 Ma 2017 [33],China 4 weeks; NS I: 5.1(0.3) years;
C: 5.3(0.6) years
I: 37/37;
C: 37/37
I: 38.6 (6.9), 21/16;
C: 37.9 (6.5), 20/17
Yu ping feng granule (oral) + Azelastine (nasal spray); Azelastine (nasal spray, one spray each nostril, twice per day) NS
 Qiu 2017 [34],China 2 weeks; NS I: 7.83(1.35) years;
C: 7.68(1.40) years
I: 50/50;
C: 50/50
I: 35.41 (7.35),28/22;
C: 36.07 (7.18),29/21
Yu ping feng granule (oral) + Ebastine (oral); Ebastine (oral, 10 mg once per day) NS
 Zheng 2017 [35],China 4 weeks; NS I: 7.7(1.3) years;
C: 8.1(1.5) years
I: 36/36;
C: 36/36
I: 42.7 (12.3),18/18;
C: 43.1 (11.6),20/16
Yu ping feng granule (oral) + Levocetirizine (oral); Levocetirizine (oral, 5 mg once per day) No AE
4 YPFS + pharmacotherapy vs pharmacotherapy vs YPFS
 Yu 2012 [23], China 14 days; NS I: 2.7 (0.5) years;
C1: 2.8 (0.4) years;
C2: 2.5 (0.6) years
I: 60/60;
C1: 60/60;
C2: 60/60;
I:32.9 (6.4), 33/27;
C1: 34.0 (5.9), 31/29;
C2: 33.0 (6.1), 32/28
YPFS plus Cang er zi san (oral) C1: Azelastine Hydrochloride (nasal spray, one spray each nostril, twice per day);
C2: YPFS plus Cang er zi san (oral) + Azelastine Hydrochloride (nasal spray, one spray each nostril, twice per day)
I: no AE;
C1 and C2: dryness in the nasal cavity (6)
  1. Note: RCT: randomized controlled trial; YPFS: yu ping feng san; M/F: male/female; I: intervention group; C: control group; NS: not stated; SD: standard deviation; AE: adverse event